© 2017 Evestra, Inc.

Board of Directors and Observers

The company’s Board of Directors currently consists of Dr. Shaked, Dr. Nickisch, Mr. Arpad Götze and two members of the Texas Biomedical Research Institute Board of Trustees, John C. Kerr and Richard T. Schlosberg. In addition, Evestra’s Board benefits from the experience of a key observer, Mr. Lutz Lingnau.

Mr. Kerr was Interim President of Texas Biomedical Research Institute (formerly SFBR) from 2006 until 2008 and served as Chairman of the TX Biomed Board of Trustees from 1998 until 2007. Since 1992, he has been active in venture capital investment in the life sciences, as an early-stage investor, either personally or through a managed fund, or board member in a number of drug development ventures including BioNumerik Pharmaceuticals, Inc., ILEX Oncology, Brava Therapeutics and Azaya Therapeutics, Inc., where he served as chairman. In the 1980s, Mr. Kerr served as Chairman and CEO of American Century Corp., a New York Stock Exchange-listed financial services company, and previously was a partner with the Houston law firm Andrews & Kurth and the San Antonio firm Cox & Smith. Mr. Kerr received his B.A. from Stanford University and his J.D. from The University of Texas School of Law.

Mr. Schlosberg is the former Publisher and CEO of the Los Angeles Times and is a member of the Board of the Texas Biomedical Research Institute. He is the immediate past President and CEO of the David and Lucile Packard Foundation, one of the nation’s largest philanthropic foundations. Additionally, Mr. Schlosberg is a board member of the Kaiser Family Foundation. He is a founding director of the Bank of San Antonio and the United States Air Force Academy Endowment, a charitable foundation supporting the Air Force Academy. He serves on the board of the San Antonio Area Foundation and the San Antonio Medical Foundation. Mr. Schlosberg graduated from the United States Air Force Academy and earned a master’s degree with honors from the Harvard Business School. He served five years as an Air Force pilot and is a veteran of the Vietnam War.

John Kerr



Richard T. Schlosberg III.


Mr. Götze has 32 years of experience in the pharmaceutical industry. Since 1998 he has held the position of Director of Business Development at Gedeon Richter Plc., Hungary, and is a Director of PregLem SA, the Swiss based affiliate of Richter. Mr. Götze joined Gedeon Richter in 1990 as Head of the API Export Department, and later became Director of International Sales. After that he served four years as head of Richter's affiliate in Spain. From 1983 to 1990 he worked with Medimpex, the Hungarian international trading company for pharmaceuticals. Mr. Götze graduated as an economist from the Budapest University of Economics in 1983.

Árpád Götze


Mr. Lingnau has been a leader in the pharmaceutical industry for more than 35 years.  While at Schering AG, he quickly moved up the ranks, taking roles of increasing responsibility in marketing and science, eventually becoming a member of the Schering Executive Board of Directors, Vice Chairman of Schering Berlin, Inc., and a member of the Board of Directors of PhRMA until his retirement in 2006. In addition to serving as advisor to the Evestra Board, Mr. Lingnau is currently on the Board of Directors of Nektar Therapeutics (San Carlos, CA).

Lutz Lingnau